Fighting to End Animal Testing

Drug and cosmetic developers are still mandated to test on animals, even if it doesn't benefit the science.
This leads to the experimentation on and death of hundreds of millions of primates, dogs, rabbits, mice and other animals.
Here's how BICO is replacing outdated methods for drug discovery to end animal testing once and for all.
3D BIOPRINTING
Fabricate human tissue samples that provide more physiologically relevant drug testing than animals.
In vitro human tissue models
Skin, ocular, oral, respiratory, and intestinal tissue models to replicate toxicity and efficacy of human cells.
automated precision dispensing
Accurately & reproducible distribute physiologically relevant biological material.
In Vitro assays for drug screening and toxicity assessment
High content screening, confocal microscopy, ELISA, and other assays.
single large-particle sorting and dispensing
Handling complex 3D cellular models such as spheroids, organoids which can replace animal testing in pre-clinical research.

BICO customers reducing animal testing

Changing the Future of Women’s Health
More relevant alternative to testing women’s personal care products on animals.

Good Clean Love is advocating for the use of a 3D model of human tissue developed by MatTek as a more relevant alternative to testing women’s personal care products on animals.

“There are currently so many problems with women’s healthcare products. Partly, because they depend on archaic animal testing to approve new products. A lot of research shows that animal testing results do not provide an accurate reflection of safety.”

Wendy Strgar, CEO at Good Clean Love

BICO endorses the FDA Modernization Act

Allowing drug and cosmetic makers to develop new products using non-animal models.
Contact your representative
Take action and help pass the FDA Modernization Act today

We have endorsed the bipartisan FDA Modernization Act of 2021 in the United States. The bill, H.R. 2565 / S.2952, would allow drug and cosmetic makers to develop new products using non-animal models including cell-based assays, organ chips and micro physiological systems, sophisticated computer modeling, and other human biology-based test methods.

“Human tissue replacement models are undoubtably a better indicator of toxicity and efficacy than dogs or mice, which share very little physiology to humans. By giving researchers the choice of testing on animals or human-models, we’ll ultimately enable them to make the best decision based on the science.”

Alex Armento, President of MatTek, a BICO group company.

Initiatives at a glance

Press release June 23, 2021

One step closer replacing animal testing with more human-relevant methods

MatTek EpiDerm ™ skin model has been approved by the OECD as a stand-alone in-vitro test method for phototoxicity.

Press release November 24, 2021

Creating awareness on how to reduce animal testing

CELLINK has joined The Swedish 3Rs Center (Replace, Reduce and Refine), network that facilitates contact and information sharing on animal-free methods to educate the research community of the humane biological methods available to improve drug development efficiency and effectiveness.
Press release December 14, 2021

BICO Endorses FDA Modernization Act of 2021

BICO announced today it is endorsing the bipartisan FDA Modernization Act of 2021. The bill, H.R. 2565 / S.2952, would allow drug and cosmetic makers to develop new products using non-animal models including cell-based assays, organ chips and micro physiological systems, sophisticated computer modelling, and other human biology-based test methods.
16 December, 2021

BICO Endorses FDA Modernization Act of 2021

20 December, 2021

The FDA Modernization Act Can Save Millions Of Animals

White paper

In Vitro vs In Vivo: Advanced Models to Replace Animals

9 June, 2022

US House Passes Legislation to end FDA Animal Testing Mandate

Contact your representative

Take action and help pass the FDA Modernization Act today